Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 708,000 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [2] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [2] - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.17 million yuan, and 1.1 million yuan respectively [2] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [1] - More than half of the company secretaries hold a bachelor's degree, with 9% having an associate degree, 52% a bachelor's degree, and 39% a master's degree [1] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [2] - The top five companies with the most investor meetings conducted 520, 437, 325, 323, and 291 meetings respectively [3]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for secretaries in the A-share pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] - The top five highest-paid secretaries have salaries ranging from 1.0832 million to 1.9309 million yuan, with varying years of service [7] Age and Education Demographics - The majority of company secretaries (60%) are aged between 30 and 50 years, while 38% are over 50 years, and only 2% are 30 years or younger [1] - More than half (52%) of the secretaries hold a bachelor's degree, with 39% holding a master's degree and 9% holding an associate degree [3] Investor Relations - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - The five companies with the highest number of investor meetings range from 291 to 520 meetings per year, with their secretaries' salaries varying widely [9]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the A-share raw material pharmaceutical sector is 608,400 yuan [5] - The distribution of salaries shows that 49% earn below 500,000 yuan, 40% earn between 500,000 and 1 million yuan, and 11% earn above 1 million yuan [5] Age and Education Distribution - Company secretaries aged between 30 and 50 constitute 60% of the market, while those over 50 account for 38%, and those aged 30 or below make up 2% [3] - Over half of the company secretaries hold a bachelor's degree, with the breakdown being 9% with an associate degree, 52% with a bachelor's degree, and 39% with a master's degree [3] Top and Bottom Salaries - The top five highest-paid company secretaries have annual salaries of 1.9309 million yuan, 1.514 million yuan, 1.2 million yuan, 1.176 million yuan, and 1.0832 million yuan, respectively [7] - The three lowest-paid company secretaries earn 174,200 yuan, 187,500 yuan, and 190,700 yuan, all of whom have served in their positions for less than two years [7] Investor Engagement - There is significant variation in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually [9] - Five companies reported zero investor meetings, while the top five companies for investor engagement had between 291 and 520 meetings, with corresponding secretary salaries ranging from 267,000 yuan to 444,200 yuan [9]

Core Viewpoint - Weier Pharmaceutical (603351.SH) announced a plan for shareholders to reduce their stakes through centralized bidding, with a focus on the employee stock ownership platform, Shuntai Zonghua [1] Group 1: Shareholder Reduction Plan - Shuntai Zonghua intends to reduce its holdings by up to 1,354,390 shares, representing no more than 1% of the total share capital, between August 20, 2025, and November 17, 2025 [1] - The company's vice president, Zou Jianguo, plans to indirectly reduce his holdings by up to 90,089 shares, while supervisor Li Youhong will reduce his holdings by up to 25,633 shares, both not exceeding 25% of their indirect holdings [1] - The reduction plan does not include shares held by the company's controlling shareholders and actual controllers, Wu Renrong, Gao Zhengsong, and Chen Xinguo, who will not reduce their stakes in any manner [1] Group 2: Pledged Shares - As of the latest disclosure, Wu Renrong, Gao Zhengsong, Chen Xinguo, and Shuntai Zonghua have pledged a total of 26,680,000 shares, accounting for 46.90% of their holdings and 19.70% of the company's total share capital [2] - Wu Renrong holds 18,521,981 shares (13.68%), with 8,570,000 shares pledged, while Gao Zhengsong and Chen Xinguo hold 14,111,986 shares (10.42%) each, with 8,460,000 and 5,350,000 shares pledged respectively [3] Group 3: Company Financials - Weier Pharmaceutical raised a total of 591,667,850.00 yuan from its initial public offering, with a net amount of 538,497,386.71 yuan intended for projects including a 20,000t/a injection drug excipient and general pharmaceutical excipient production base [4] - The total issuance costs amounted to 53,170,463.29 yuan, with underwriting and sponsorship fees of 41,509,433.96 yuan [5]

Policy Developments - The National Medical Products Administration (NMPA) has released a draft for public consultation regarding the adjustment of medical device classifications, aiming to optimize the registration and filing requirements for medical devices [1] Drug Approval - Yuyuan Pharmaceutical's YKYY029 injection has received clinical trial approval for treating hypertension, marking a significant step in the development of a novel siRNA drug [2] - Hengrui Medicine has received clinical trial approvals for four drugs, including SHR-8068 injection and Abediterib injection, with total R&D investments amounting to approximately 20.33 million yuan [3] Financial Reports - Microchip Biotech expects a net profit of 30.06 million yuan for the first half of 2025, driven by increased sales from new drug listings and optimized sales strategies [4] - China National Pharmaceutical Modern reported a 6.46% decline in net profit for the first half of the year, attributed to decreased sales and prices of certain antibiotics and other products [5] Capital Market - Tigermed announced the sale of its stake in Lixin Pharmaceutical for approximately 34.11 million USD, reflecting a strategic move in the context of the domestic pharmaceutical industry's consolidation [6] Industry Events - A breakthrough in brain-computer interface technology has been achieved in Shanghai, allowing patients with speech impairments to communicate through decoded brain activity [8] - Yuan Da Pharmaceutical's innovative nasal spray for dry eye treatment has received approval and its first prescriptions have been issued, providing a new treatment option for patients [9] Debt Resolution - Kangmei Pharmaceutical has reached a settlement agreement to resolve historical debt issues for 43.5 million yuan, facilitating the closure of related legal matters [10] Market Sentiment - Weier Pharmaceutical announced plans for its employee stock ownership platform to reduce its holdings by up to 1% of the company's shares, driven by shareholder funding needs [11]

Summary of Key Points Core Viewpoint - The announcement details a share reduction plan by a major shareholder of Nanjing Weier Pharmaceutical Group Co., Ltd., indicating a strategic move to meet funding needs while maintaining control over the company by its major stakeholders [1][2]. Group 1: Major Shareholder Information - Nanjing Shuntai Zonghua Venture Investment Partnership (Limited Partnership) holds 10,142,990 shares, representing approximately 7.49% of the total share capital of the company [1][2]. - The shares were acquired through pre-IPO holdings and capital reserve conversion after the IPO [1][2]. Group 2: Share Reduction Plan Details - The shareholder plans to reduce holdings by up to 1,354,390 shares, which is not more than 1% of the total share capital, through centralized bidding from August 20, 2025, to November 17, 2025 [1][2]. - The reduction does not include shares held indirectly by the company's controlling shareholders and actual controllers [1][2]. Group 3: Shareholder Commitments - Senior management has made commitments regarding share transfer limits, stating that during their tenure, they will not transfer more than 25% of their total shareholdings annually after the lock-up period [4]. - The commitments also include a restriction on transferring shares for six months post-resignation [4]. Group 4: Compliance and Regulatory Framework - The share reduction plan complies with relevant laws and regulations, including the Securities Law and the Shanghai Stock Exchange rules [5]. - The company will monitor the progress of the share reduction and fulfill its information disclosure obligations [5].

证券代码：603351 证券简称：威尔药业 公告编号：2025-021 南京威尔药业集团股份有限公司 关于股东集中竞价减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 股东名称 | 南京舜泰宗华创业投资合伙企业（有限合伙） | | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 √是 □否 | | | 直接持股 5%以上股东 √是 □否 | | | 董事、监事和高级管理人员 □是 √否 | | 持股数量 | 10,142,990股 | | 持股比例 | 7.49% | | 当前持股股份来源 | IPO 前取得：5,174,995股 | | | 其他方式取得：4,967,995股 | 一、减持主体的基本情况 1 | | 股东名称 | 持股数量（股） | 持股比例 | 一致行动关系形成原因 | | --- | --- | --- | --- | --- | | | 南京舜泰宗华创 | | | | | | 业投资合伙企业 | 10,142,990 | 7.49% ...

Core Viewpoint - The employee stock ownership platform of Weier Pharmaceutical plans to reduce its holdings by up to 1% of the company's total shares due to shareholder funding needs [1] Summary by Relevant Sections Company Actions - Weier Pharmaceutical (603351.SH) announced that its employee stock ownership platform, Shuntai Zonghua, intends to reduce its holdings by a maximum of 1,354,390 shares, which represents up to 1% of the company's total share capital [1] Reasons for Action - The reduction in shareholding is attributed to the funding needs of the shareholders [1] Shareholding Details - The shares to be reduced are sourced from those held prior to the company's initial public offering [1]

Core Viewpoint - Weir Pharmaceutical (603351) has announced a cash dividend of 0.40 CNY per share, with the A-share registration date set for June 12, 2025, and the dividend payment date on June 13, 2025 [1] Company Announcement Summary - Weir Pharmaceutical's stock closed at 28.01 CNY on June 6, 2025, reflecting a 0.57% increase from the previous week [1] - The company reached a weekly high of 29.1 CNY on June 4, 2025, and a low of 27.49 CNY on June 3, 2025 [1] - The total market capitalization of Weir Pharmaceutical is currently 3.794 billion CNY, ranking 116th out of 150 in the chemical pharmaceutical sector and 3655th out of 5148 in the A-share market [1] - The cash dividend distribution will be based on a total share capital of 135,439,132 shares, amounting to a total cash dividend payout of 54,175,652.80 CNY [1] - Tax implications for shareholders include a 10% withholding tax for certain categories of investors, resulting in a net cash dividend of 0.36 CNY per share for those subject to tax [1]

证券代码：603351 证券简称：威尔药业 公告编号：2025-020 重要内容提示： ● 每股分配比例 A股每股现金红利0.40元 一、通过分配方案的股东会届次和日期 本次利润分配方案经公司2025年5月15日的2024年年度股东会审议通过。 2.分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分公司（以下简 称"中国结算上海分公司"）登记在册的本公司全体股东。 3.分配方案： 南京威尔药业集团股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 三、相关日期 ■ 四、分配实施办法 股东吴仁荣、高正松、陈新国、唐群松、南京舜泰宗华创业投资合伙企业（有限合伙）的现金红利由公 司自行发放。 3.扣税说明 （1）对于持有公司无限售条件流通股的自然人股东及证券投资基金，根据《关于实施上市公司股息红 利差别化个人所得税政策有关问题的通知》（财税[2012]85 号）及《关于上市公司股息红利差别化个人 所得税政策有关问题的通知》（财税[2015]101号）的有 ...